Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Off Trail, On Track: an Exercise in Clinical Reasoning.

Zejnullahu K, Santhosh L, Mourad M, Connor DM.

J Gen Intern Med. 2019 Oct;34(10):2282-2287. doi: 10.1007/s11606-019-05095-3. Epub 2019 Jul 3. No abstract available.

PMID:
31270781
2.

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ.

Clin Genitourin Cancer. 2017 Dec;15(6):733-741.e1. doi: 10.1016/j.clgc.2017.05.026. Epub 2017 Jun 3.

PMID:
28655452
3.

Approaches to minimize castration in the treatment of advanced prostate cancer.

Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R.

Urol Oncol. 2016 Aug;34(8):368-74. doi: 10.1016/j.urolonc.2016.02.001. Epub 2016 Mar 2. Review.

PMID:
26944450
4.

Diffuse Alveolar Hemorrhage: Blood, Sweat and Tears.

Zejnullahu K, Khatami S, Manesh RS.

J Gen Intern Med. 2016 Jul;31(7):812-3. doi: 10.1007/s11606-016-3593-6. Epub 2016 Feb 18. No abstract available.

5.

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.

Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H.

Elife. 2015 Jun 5;4:e06907. doi: 10.7554/eLife.06907.

6.

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA.

Cancer Res. 2013 Jan 15;73(2):834-43. doi: 10.1158/0008-5472.CAN-12-2066. Epub 2012 Nov 19.

7.

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.

Lockwood WW, Zejnullahu K, Bradner JE, Varmus H.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19408-13. doi: 10.1073/pnas.1216363109. Epub 2012 Nov 5.

8.

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA.

Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442.

9.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.

Cancer Cell. 2010 Jan 19;17(1):77-88. doi: 10.1016/j.ccr.2009.11.022.

10.

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.

Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA.

Oncogene. 2010 Apr 22;29(16):2346-56. doi: 10.1038/onc.2009.526. Epub 2010 Feb 1.

11.

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA.

Clin Cancer Res. 2008 Nov 1;14(21):6963-73. doi: 10.1158/1078-0432.CCR-08-0957.

12.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA.

Clin Cancer Res. 2008 Jul 1;14(13):4275-83. doi: 10.1158/1078-0432.CCR-08-0168.

13.

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA.

Cancer Res. 2007 Dec 15;67(24):11924-32.

14.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.

Science. 2007 May 18;316(5827):1039-43. Epub 2007 Apr 26.

15.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA.

J Clin Invest. 2006 Oct;116(10):2695-706. Epub 2006 Aug 10.

Supplemental Content

Loading ...
Support Center